￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Oncology

Dacomitinib, a new targeted drug for lung cancer, can significantly extend the survival time of advanced lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
The advent of dacomitinib has changed the treatment landscape of EGFR-positive lung cancer!

2025-10-19 11:44:20

Check Details
Contraindications and precautions for patients with lung cancer taking dacomitinib

2025-10-19 11:44:20

Check Details
None

2025-10-19 11:44:20

Check Details
Phase III clinical trial of dacomitinib in the treatment of locally advanced or metastatic non-small cell lung cancer carrying EGFR_ Kanghule

2025-10-19 11:44:20

Check Details
What are the differences between the second-generation targeted drug for lung cancer, dacomitinib, and the first-generation drug?

2025-10-19 11:44:20

Check Details
Effects and effects of crizotinib (Xalkori) on ROS1 mutated lung cancer

2025-10-19 11:44:20

Check Details
Cabozantinib (XL184) is a potent ROS1 inhibitor_ Kangxi

2025-10-19 11:44:20

Check Details
How about crizotinib (Xalkori) in treating lung cancer?

2025-10-19 11:44:20

Check Details
Does the targeted drug vandetanib have an effect on patients with RET mutations in lung cancer?

2025-10-19 11:44:20

Check Details
Which patients with lung cancer can vandetanib be used to treat?

2025-10-19 11:44:20

Check Details
Ramucirumab + docetaxel for metastatic non-small cell lung cancer that worsens during or after platinum-containing chemotherapy_ Kanghule

2025-10-19 11:44:20

Check Details
Category
相关知识